INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

INmune Bio (NASDAQ:INMB) posted its quarterly earnings data on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.09), Fidelity Earnings reports.

Shares of NASDAQ INMB traded down $0.16 during trading hours on Friday, hitting $4.52. 8,200 shares of the stock were exchanged, compared to its average volume of 20,034. The company has a debt-to-equity ratio of 0.01, a current ratio of 20.94 and a quick ratio of 20.94. The company’s 50 day moving average is $4.94 and its 200 day moving average is $7.92. INmune Bio has a one year low of $3.51 and a one year high of $11.50.

In other news, Director Scott Juda bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was acquired at an average price of $6.00 per share, for a total transaction of $30,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have purchased a total of 12,918 shares of company stock valued at $77,109 in the last quarter. 67.67% of the stock is currently owned by corporate insiders.

INMB has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $11.50 price objective on shares of INmune Bio in a report on Thursday, September 12th. Maxim Group set a $13.00 price objective on shares of INmune Bio and gave the stock a “buy” rating in a report on Friday, September 13th.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Recommended Story: Inverted Yield Curve

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.